Uz izvinjenje, što je ceo tekst na Engleskom jeziku, ako ste u mogućnosti, pročitajte dole navedene informacije (detalji uvek mogu da se prevedu na naš jezik, ako za to postoji opravdana potreba, odnosno neka konkretna korist!)
ProtAb Ltd. je farmaceutska kompanija iz Izraela i bavi se istraživanjem lekova protiv autoimunih bolesti, zasnovanih na "monoklonalnim antitelima" ("monoclonal antibodies") Da pojednostavim objašnjenje -- ovde se praktično radi samo o novoj generaciji bioloških lekova!
"ProximAb" je lek za reumatoidnih artritis, ali deluje i na druge autoimune bolesti, kao što su ove naše zapaljenske bolesti creva. Dobro je da se vrše razna istraživanja, ali, na žalost, još uvek je sve ovo nedovoljno dobro, da bi se bolesti potpuno izlečile!
U večitoj nadi da ćemo dočekati i taj 'čudotvorni' lek, koji će nas osloboditi ovog užasnog 'tereta',
PS: Slede detalji u vezi sa "ProximAb"-om....
Sub-Sector: Antibody, Immunotherapy & Vaccines
Medical Field: Autoimmune Diseases
ProtAb is focused on the development of novel therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. ProtAb’s therapeutic approach is uniquely based on stimulating a molecule that suppresses inflammation, unlike current drugs on the market which are designed to suppress molecules that stimulate inflammation.
The Company’s first product – ProximAb – is a promising monoclonal antibody for the treatment of rheumatoid arthritis (RA). ProtAb has established preclinical proof-of-concept for ProximAb, demonstrating promising activity in various experimental autoimmune disease models of RA. Thus far, ProtAb has successfully completed the humanization of ProximAb and evaluation of efficacy both in vitro and in vivo. Advanced preclinical development is ongoing on the pathway towards cell line development, GMP manufacturing and testing, and initiation of a clinical trial in RA. The Company will also conduct proof-of-concept preclinical studies of ProximAb in animal models of inflammatory bowel disease (IBD) and psoriasis.
Science and Technology:
ProtAb’s first product is ProximAb, a humanized monoclonal antibody with a unique mechanism of action, which is being developed as a pro-anti-inflammatory agent for the treatment of RA and other autoimmune diseases. Autoimmune diseases such as RA are characterized, among other things, by an imbalance in cytokine expression. ProtAb’s approach takes RA therapy one step beyond that of today’s blockbuster RA medications, Enbrel, Remicade and Humira. These drugs are anti-pro-inflammatory, and act by inhibiting the pro-inflammatory protein TNFa. While providing a marked improvement in symptoms, current RA drugs can only reduce symptoms by 50% (ACR50) in about half of the treated patients and are associated with serious side effects. Thus, there is a definite need for new, innovative therapeutic approaches in RA.
ProximAb is directed against a 16-amino acid surface epitope (termed peptide-6) of the bacterial heat shock protein 65 (HSP65). ProtAb’s scientists have found that significantly fewer RA patients have natural antibodies against peptide-6 than do healthy individuals. Furthermore, ProximAb antibodies interact not only with peptide-6, but moreover they cross react directly with a surface ligand on macrophages, and this interaction is the key to the mechanism of action of these antibodies. Following binding of the ProximAb antibodies to macrophages, there is activation of a signal transduction pathway that leads to an increase in production and secretion of cytokines, specifically IL-10, that instruct the body to end the inflammatory process. This tilts the balance from pro-inflammatory signals, such as TNF-alpha, to anti-inflammatory signals, such as IL-10.
Scientific & Management Team:
ProtAb’s scientific team is spearheaded by Prof. Yaakov Naparstek, Chairman of Medicine at Hadassah University Hospital, who is the company’s founder and a pioneer in the fields of autoimmunity and arthritis. ProtAb’s management is comprised of highly experienced individuals from Hadasit, Hadasit Bio-Holdings and the Israeli biotechnology industry.
Intellectual Property Status:
ProtAb has a strong IP estate, where the core patent application (PCT/IL99/00595) has a field of interest covering HSP65 peptides and antibodies against them for use against autoimmune or inflammatory disorders, including RA among others.
Collaboration / Investment Opportunity:
ProtAb is currently in the process of raising funds from local and foreign investors and venture capital funds. The immediate investment will be used for completion of pre-clinical development and testing of ProximAb for RA and additional applications, local and IND submissions, and execution of a Phase I/II clinical trial in RA. In addition, ProtAb welcomes partnership and collaboration discussions.
Predavanja o Crohn-ovoj bolesti i ulceroznom kolitisu, njihovom lečenju, kao i informacije o novostima iz sveta medicine.
1 post • Stranica 1 od 1
Bolest: Crohn-ova, od 1991. / Operisan: 3 puta / Lekovi (do sada): Orvagil, Ciprocinal, Dexason, Pronison, Salazopyrin, 5-ASA, Salofalk, Pentasa, Asacol, Imuran i Methotrexate / Aktuelna terapija: Nema (zbog netolerancije na imunosupresive!)
Ko je OnLine
Korisnika u ovom forumu: Nema registrovanih korisnika i 7 gosta